The chemotherapeutic agent bleomycin in a two-drug combination with zidovudine, ritonavir or indinavir synergistically inhibits HIV type-1 replication in peripheral blood lymphocytes

International Journal of Antimicrobial Agents

Volumn 18, Issue 6, 2001, Pages 513-518

  Georgiou, Niki A ^a   Van der Bruggen, Tjomme ^b   Jansen, Christine A ^b   Oudshoorn, Maroeska ^a   Nottet, Hans S L M ^b   Marx, Joannes J M ^a,b   Van Asbeck, B Sweder ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bleomycin; HIV 1; Indinavir: Ritonavir; Synergy; Zidovudine

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BLEOMYCIN; INDINAVIR; RITONAVIR; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG SYNERGISM; HIV-1; HUMANS; INDINAVIR; LEUKOCYTES, MONONUCLEAR; MICROBIAL SENSITIVITY TESTS; RITONAVIR; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0035217889     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(01)00453-8     Document Type: Article

References (16)

1. Treatment of the acquired immunedeficiency syndrome-related Kaposi's sarcoma with bleomycin as a single agent
2. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: A prospective, multi-institutional AIDS clinical trials group study (ACTG 149)
3. Hodgkin's disease in 35 patients with HIV infection: An experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF
4. Chemotherapy for HIV-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy (HAART) is not associated with excessive toxicity
5. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma
6. Low dose methotrexate, bleomycin, adriamycin, cyclophosphamide, oncovin, and dexamethasone with zalcitabine in patients with AIDS related lymphoma: Effect on HIV and serum IL-6 levels over time
7. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin
8. A clinical review of bleomycin - A new antineoplastic agent
9. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates
10. Dissociation of gp120 from HIV-1 virions induced by soluble CD4
11. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: Effects of infectivity and neutralization
12. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
13. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
14. Bleomycin pharmacokinetics in man. I. Intravenous administration
15. Bleomycin pharmacokinetics in man. II. Intracavitary administration